Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration has approved Depomed's post-herpetic neutalgia (PHN) treatment, Gralise (gabapentin) tablets.
Subscribe to our email newsletter
The once daily tablet, Gralise is developed by Depomed and it is licensed to Abbott Products in US, Mexico and Canada.
Depomed CEO Carl Pelzel said the approval of Gralise is a major step toward achieving their key strategic objective of sustainable profitability in 2011 and beyond.
Depomed Research and Development vice president Michael Sweeney said FDA has granted Gralise Orphan Drug status, recognizing Gralise as an important treatment option for patients who suffer from the pain of PHN.